+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Compound heterozygosity of HLA-DRB3*01:01 and HLA-DRB4*01:01 as a potential predictor of fetal neonatal alloimmune thrombocytopenia

Compound heterozygosity of HLA-DRB3*01:01 and HLA-DRB4*01:01 as a potential predictor of fetal neonatal alloimmune thrombocytopenia

Transfusion 53(2): 344-352

Fetal neonatal alloimmune thrombocytopenia (FNAIT) is a life-threatening bleeding disorder in the fetus or neonate caused by maternal alloantibodies directed against fetal platelet (PLT) antigens inherited from the father. The immune-dominant antigen leading to severe FNAIT is the human PLT antigen (HPA)-1, whose polymorphism constitutes an epitope for human leukocyte antigens (HLAs), usually DRB3*0101 leading to an immune response. In this study our aims were to find whether other allele variants of the β subunit of the HLA-DR family specifically focused on the HLA residues that bind Position 33 of the HPA-1 integrin contribute to FNAIT development and affect response to treatment and whether coexistence of both anti-HPA-1a and anti-HLA class I specific against the father's antigens leads to a more severe thrombocytopenia in the newborn. We examine the genotype of 23 mothers to newborns with FNAIT compared to a control group. Our results suggested that, when HPA-1 incompatibility with the husband is found, the presence of two HLA alleles (DRB3*01:01 and DRB4*01:01) in the mother increases the risk and severity of FNAIT and reduces the success of a preventive immunoglobulin G treatment. We provide a structural model for the molecular basis of the rational effects of the different HLA alleles. In addition, we found that the presence of both anti-HPA-1 and anti-HLAs did not aggravate FNAIT in comparison to mothers harboring only anti-HPA-1. Overall, we suggest that a specific genotyping of the mother in relation to HLA-DRB as well as HPA-1 can serve as an antenatal diagnostic tool, particularly in siblings of women who gave birth to neonates with FNAIT.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 052269097

Download citation: RISBibTeXText

PMID: 22671039

DOI: 10.1111/j.1537-2995.2012.03734.x

Related references

HLA-DRB3*01:01 is a predictor of immunization against human platelet antigen-1a but not of the severity of fetal and neonatal alloimmune thrombocytopenia. Transfusion 57(3): 533-540, 2016

T-cell responses associated with neonatal alloimmune thrombocytopenia: isolation of HPA-1a-specific, HLA-DRB3*0101-restricted CD4+ T cells. Blood 113(16): 3838-3844, 2009

Contemporary management of neonatal alloimmune thrombocytopenia: good outcomes in the intravenous immunoglobulin era: results from the Australian neonatal alloimmune thrombocytopenia registry. Journal of Maternal-Fetal and Neonatal Medicine 30(20): 2488-2494, 2016

Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs. Immune Thrombocytopenia Working Group. American Journal of Perinatology 13(7): 423-431, 1996

Anti-HPA-5b-induced neonatal alloimmune thrombocytopenia: Antibody titre as a predictor. British Journal of Haematology 110(1): 223-227, 2000

Prediction of fetal status in fetal/neonatal alloimmune thrombocytopenia (FNAIT)?. Blood 118(9): 2637-8; Author Reply 2639-40, 2011

Fetal/neonatal alloimmune thrombocytopenia. Thrombosis Research 131 Suppl 1: S42-S46, 2013

Fetal-neonatal alloimmune thrombocytopenia. Anales de Pediatria 58(6): 562-567, 2003

Fetal and neonatal alloimmune thrombocytopenia. Ceska Gynekologie 83(6): 448-451, 2019

Fetal and neonatal alloimmune thrombocytopenia. Best Practice and Research. Clinical Obstetrics and Gynaecology 22(1): 3-14, 2007

Fetal and neonatal alloimmune thrombocytopenia. Seminars in Fetal and Neonatal Medicine 21(1): 19-27, 2016

Fetal and neonatal alloimmune thrombocytopenia. Schweizerische Medizinische Wochenschrift 123(35): 1655-1661, 1993

OP05.01: Correlation between isolated fetal cerebral ventriculomegaly and fetal and neonatal alloimmune thrombocytopenia. Ultrasound in Obstetrics & Gynecology 42(S1): 59-60, 2013

Omission of fetal sampling in treatment of subsequent pregnancies in fetal-neonatal alloimmune thrombocytopenia. American Journal of Obstetrics and Gynecology 215(4): 471.E1-9, 2017

EP21.08: Antenatal management of fetal neonatal alloimmune thrombocytopenia (FNAIT) and neonatal outcome according to the category of risk. Ultrasound in Obstetrics & Gynecology 48 Suppl 1: 357-357, 2016